MORE►
cancer
Bridge Labs at Pegasus Park is at right with the campus's 18-story office tower literally bridged to it on the left. [Photo: Mauricio Rojas]
Madrid-Based Cancer Diagnostics Co. Snags Biggest Spec Suite at Pegasus Park’s Bridge Labs
by Lance Murray | Jan 23, 2025
Founded in 2012, Universal DX is focused on "cracking cancer’s code" via its multi-omics and machine learning models. Starting with colorectal cancer, it's building a "multi-cancer platform" that can ID the unique DNA regions associated with different types of cancers.
by Lance Murray |
Jan 18, 2025
The project, led by Assistant Professor of Biology Alicia Rogers, could lead to improved genetic knowledge that may aid in the development of synthetic therapies to prevent or treat diseases, including cancer.
MORE►
by Lance Murray |
Jul 17, 2024
Researchers at UT Southwestern Medical Center in Dallas have identified a compound that selectively eliminates cancer cells while sparing immune cells in a form of cell death known as ferroptosis, according to a news release.
UTSW said the findings, published in Science Translational Medicine earlier this year, could lead to new treatments for a wide variety of cancer types....
MORE►
by Lance Murray |
Feb 27, 2024
Included in the 12 Dallas-area funding awards is a $4 million Rising Star grant to bring Stefan Gloeggler, Ph.D., to UT Southwestern Medical Center from the Max Planck Institute of Multidisciplinary Sciences in Göttingen, Germany.
MORE►
UTA Associate Professor Suvra Pal, right, and his student student Wisdom Aselisewine, left, published a new model predicting survival of cancer. [Sources: UTA photos, istockphoto background]
UTA Study Shows Machine Learning Technique Is 30% Better at Predicting Cancer Cure Rates
by Lance Murray | Dec 6, 2023
UT Arlington principal investigator Dr. Suvra Pal said that previous studies modeling the probability of a cancer cure—also called the cure rate—"used a generalized linear model." The new statistical modeling method published by Pal and his student is said to be 30% more effective in predicting who will be cured of cancer and who will need further treatment.
MORE►
by David Seeley |
Sep 18, 2023
The award will help SMU biology professor Zhihao Wu determine if different "quality control pathways" in our bodies might be working together to repair damaged components in cells. The research could help lead to "new therapeutic targets" for hallmarks known to cause many human diseases, the university said.
MORE►
by Lance Murray |
Aug 17, 2023
The 29 new grants approved by CPRIT's Oversight Committee include the first CPRIT Scholar award to Southern Methodist University in Dallas and state funding for Dallas' Baylor Research Institute to join a major National Cancer Institute study.
MORE►
by Lance Murray |
Mar 13, 2023
“Our researchers continue to push the envelope on developing a better understanding of cancer and new ways to help cancer patients in Texas and beyond,” said Center Director Carlos L. Arteaga, M.D.
MORE►
NanOlogy Chief Medical Officer Gere DiZerega at far left speaking at 2019 BIO CEO and Investor Conference. [Video still: NanOlogy]
Fort Worth Biotech NanOlogy Gets U.S. Patent for New Cancer Treatment
by Lance Murray | Mar 7, 2023
NanOlogy said the new patent covers a method of treating cancer by intratumoral administration of large surface area microparticle taxanes in combination with systemic administration of immune checkpoint inhibitors. “The goal is to identify which combinations can increase the immune response, thereby increasing the overall solid tumor response to treatment," said NanOlogy Chief Medical Officer Gere DiZerega.
MORE►
by Lance Murray |
Mar 2, 2023
Dallas-based Lantern Pharma Inc. has expanded its clinical development team with the addition of Dr. Reggie Ewesuedo as vice president of clinical development, and several additional team members....
MORE►
by Lance Murray |
Feb 15, 2023
Dallas-based Financial Strategies Acquisition Corp. has acquired Texas-based preclinical pharmaceutical company Austin Biosciences Corp.
Financial Strategies is a special purpose acquisition company led by CEO Alexander V. Schinzing. It said that upon the deal’s closing, Austin Biosciences will become a wholly owned subsidiary of the company.
Earlier this month, Financial Strategies announced that its board approved an extension of the period of time available to consummate the deal by one month from Feb....
MORE►
by Kevin Cummings |
Jun 23, 2022
Two giants in their industry are teaming up to accelerate cancer research. The new joint venture is an "important step forward" to increase access to clinical trials, says McKesson CEO Brian Tyler, McKesson CEO.
Separate from the joint venture deal, McKesson will acquire Genospace, a personalized precision medicine platform that’s part of HCA’s research institute.
MORE►
Photo: smrm1977/iStock
Westlake’s Virbac Announces Availability of New Dog Cancer Treatment Across the U.S.
by David Seeley | Aug 16, 2021
Stelfonta received FDA approval last November to treat dogs with non-metastatic, skin-based mast cell tumors (MCTs)—the most common malignant skin tumor in dogs. The injection is now available at vet clinics across the U.S., with an 88% "satisfactory experience" rate to date.
MORE►
by Alex Edwards |
Jun 17, 2021
The investment was led by Advantech Capital, a PE fund based in China that focuses on TMT, pharmaceuticals, and healthcare. This combined with the support from the Cancer Prevention and Research Institute of Texas (CPRIT), which granted OncoNano $9.97 million last year, will support Phase 3 clinical trials for the biotech's technology that can diagnose and treat cancer with high specificity.
MORE►
by Alex Edwards |
Jun 8, 2021
Dallas' Mary Kay Foundation has donated $150,000 to CancerCare to provide direct support to women who are most in need of financial or emotional assistance.
MORE►
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
